ICON plc — FY2017 Form 20-F Summary
Reporting period: Year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter filing; separate Q4 results are not clearly provided in the filing text. Financial statements are prepared under U.S. GAAP and presented in U.S. dollars. ICON is a global clinical research organization (CRO) serving pharmaceutical, biotechnology and medical device companies.
Financial performance
| Metric | FY2017 | FY2016 | Change / context |
|---|---|---|---|
| Gross revenue | $2.402 billion | $2.365 billion | Up 1.6% |
| Net revenue | $1.758 billion | $1.666 billion | Up 5.5%; up 4.8% in constant currency |
| Operating income | $338.3 million | $311.7 million | Up 8.5%; operating margin 19.2% vs. 18.7% |
| Net income | $281.5 million | $262.2 million | Up 7.4% |
| Diluted EPS | $5.13 | $4.65 | Up 10.3%; weighted-average diluted shares fell to 54.8 million from 56.4 million |
| Cash from operations | $383.1 million | $259.2 million | Up $123.9 million |
| Cash and short-term investments | $360.4 million | $260.6 million | Cash of $282.9 million and investments of $77.6 million at year-end |
| Working capital | $535.0 million | $463.6 million | Increased $71.4 million |
| Senior Notes | $350 million principal | $350 million principal | Fixed 3.64% interest; due December 2020 |
Net revenue growth reflected organic expansion and contributions from Mapi, acquired in July 2017, and the full-year impact of ClinicalRM. Direct costs grew 6.9%, faster than net revenue, and increased to 58.4% of net revenue from 57.7%. SG&A declined 0.6% and fell to 18.4% of net revenue from 19.5%. Income-tax provision was $46.6 million, with a 14.2% effective tax rate; the filing cites U.S. tax reform and geographic profit mix among the influences.
Cash, debt and capital allocation
- Investing cash outflow was $177.8 million, including $144.1 million paid for Mapi, $44.7 million in capital expenditure and net purchases of short-term investments.
- Financing cash outflow was $119.3 million, principally due to $133.1 million of share repurchases, partly offset by $13.9 million from option exercises. The company repurchased 1.59 million shares during 2017; $156.9 million remained under the announced $400 million program at year-end.
- No revolving-credit borrowings were outstanding at year-end. ICON reported up to $100 million available under its committed revolver and a separate $30 million uncommitted facility; both were undrawn.
- Management expected approximately $50 million of investment over the next 12 months for IT, existing facilities and new offices, and said foreseeable needs could be funded from operating cash flow, existing cash and available facilities.
Material changes, outlook and notable items
- Mapi expanded ICON’s late-phase, patient-centered outcomes, real-world evidence, commercialization and regulatory services. The acquisition added $129.2 million of provisional goodwill.
- Backlog was approximately $4.9 billion at year-end, compared with $4.2 billion a year earlier. ICON cautioned that cancellations and delays mean backlog is not a reliable guarantee of future revenue.
- Customer concentration eased: the top five customers represented 40% of net revenue versus 45% in 2016; the largest customer represented 18% versus 26%. Customer dependence remains a material risk.
- A $7.8 million restructuring charge was recorded for resource rationalization. SG&A included a $6.0 million credit from revaluing ClinicalRM contingent consideration and $3.5 million of one-time costs related to a proposed transaction.
- ASC 606 adoption beginning January 1, 2018 was expected to reduce opening shareholders’ equity by an estimated $40 million to $80 million. The estimate was provisional and subject to change; ICON planned to recognize clinical-trial service revenue over time using project costs to measure progress.
- U.S. tax reform resulted in a $7.7 million tax expense for deemed repatriation of certain historic foreign earnings. The filing states that related tax accounting estimates were provisional.
- No formal revenue or earnings guidance is provided in the filing. Management described continued outsourcing, strategic client partnerships, technology investment and targeted acquisitions as growth opportunities, while emphasizing execution, recruitment and operational efficiency.
- Key risks include fixed-fee contract cost overruns, project cancellation or delay, patient and investigator recruitment, reliance on major customers, competition and vendor consolidation, staffing, cybersecurity and data privacy, regulation, foreign exchange, and the uncertain conversion of backlog. The filing disclosed no litigation it expected to have a material adverse effect and no intended cash dividends in the foreseeable future.
Investor facts to verify
- Standalone Q4 performance and the quarterly trend in net revenue, margins and cash generation; this annual filing does not clearly provide separate Q4 figures.
- Mapi’s post-acquisition contribution, integration progress and final purchase-price allocation, which was provisional.
- The final ASC 606 opening-equity adjustment and any effects on revenue timing, contract assets and liabilities, and reported margins.
- Whether backlog converts to revenue as expected and whether the largest customer’s share of revenue continues to decline.
- Cash deployment, remaining share-buyback authorization, planned capital expenditure and compliance with debt covenants.
- The final effects of U.S. tax reform and the resolution of unrecognized tax benefits; the filing reported $23.7 million of unrecognized tax benefits at year-end.
Audit and controls: KPMG issued unqualified opinions on the FY2017 financial statements and on the effectiveness of internal control over financial reporting.